Cannabinoids: Friend or Foe?

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 6, 2015, Pages 528-531

  Le Foll, B ^a   Tyndale, R F ^b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID DERIVATIVE; DRONABINOL; ILLICIT DRUG; NABIXIMOLS; CANNABINOID; CANNABIS; MEDICAL CANNABIS;

CANNABIS ADDICTION; CANNABIS USE; COGNITIVE DEFECT; DRUG RESEARCH; DRUG USE; HUMAN; NATIONAL HEALTH ORGANIZATION; PERCEPTION; PERSONAL EXPERIENCE; PRIORITY JOURNAL; REVIEW; PHYTOTHERAPY;

CANNABINOIDS; CANNABIS; HUMANS; MEDICAL MARIJUANA; PHYTOTHERAPY;

EID: 84961755770     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.119     Document Type: Review

References (22)

1. Vemuri, V.K. & Makriyannis, A. Medicinal Chemistry of Cannabinoids. CPT Pharmacology & Therapeutics 97, 553-558 (2015).
2. Su, M.K., Seely, K.A., Moran, J.H. & Hoffman, R.S. Metabolism of Classical Cannabinoids and the Synthetic Cannabinoid JWH-018. CPT Pharmacology & Therapeutics 97, 562-564 (2015).
3. Compton, W.M., Grant, B.F., Colliver, J.D., Glantz, M.D. & Stinson, F.S. Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. JAMA 291, 2114-2121 (2004).
4. Volkow, N.D., Compton, W.M. & Weiss, S.R. Adverse health effects of marijuana use. N. Engl. J. Med. 371, 879 (2014).
5. Lev-Ran, S., Le Strat, Y., Imtiaz, S., Rehm, J. & Le Foll, B. Gender differences in prevalence of substance use disorders among individuals with lifetime exposure to substances: Results from a large representative sample. Am. J. Addict. 22, 7-13 (2013).
6. Degenhardt, L., Chiu, W.T., Sampson, N., Kessler, R.C. & Anthony, J.C. Epidemiological patterns of extra-medical drug use in the United States: Evidence from the National Comorbidity Survey Replication, 2001-2003. Drug Alcohol Depend. 90, 210-223 (2007).
7. Panlilio, L.V., Goldberg, S.R. & Justinova, Z. Cannabinoid Abuse and Addiction: Clinical and Preclinical Findings. CPT Pharmacology & Therapeutics 97, 616-627 (2015).
8. Allsop, D.J., Lintzeris, N., Copeland, J., Dunlop, A. & McGregor, I.S. Cannabinoid Replacement Therapy (CRT): Nabiximols (Sativex) as a Novel Treatment for Cannabis Withdrawal. CPT Pharmacology & Therapeutics 97, 571-574 (2015).
9. Crocker, C.E. & Tibbo, P.G. Cannabis and the Maturing Brain: Role in Psychosis Development. CPT Pharmacology & Therapeutics 97, 545-547 (2015).
10. Porath-Waller, A.J., Notarandrea, R. & Vaccarino, F.J. Young Brains on Cannabis: It's Time to Clear the Smoke. CPT Pharmacology & Therapeutics 97, 551-552 (2015).
11. Abrams, D.I. & Guzman, M. Cannabis in Cancer Care. CPT Pharmacology & Therapeutics 97, 575-586 (2015).
12. Hall, H. & Weier, M. Assessing the Public Health Impacts of Legalizing Recreational Cannabis Use in the USA. CPT Pharmacology & Therapeutics 97, 607-615 (2015).
13. Kalant, H. Cannabis Control Policy: No Rational Basis Yet for Legalization. CPT Pharmacology & Therapeutics 97, 538-540 (2015).
14. Rehm, J. & Fischer, B. Cannabis Legalization With Strict Regulation, the Overall Superior Policy Option for Public Health. CPT Pharmacology & Therapeutics 97, 541-544 (2015).
15. Centre for Addiction and Mental Health. Cannabis Policy Framework. (2014). http://www.camh. ca/en/hospital/about-camh/influencing- public-policy/Documents/CAMHCannabisPolicy Framework.pdf
16. Bolognini, D. & Ross, R.A. Medical Cannabis vs. Synthetic Cannabinoids: What Does the Future Hold? CPT Pharmacology & Therapeutics 97, 568-570 (2015).
17. Fowler, C.J. Delta9-Tetrahydrocannabinol and Cannabidiol as Potential Curative Agents for Cancer: A Critical Examination of the Preclinical Literature. CPT Pharmacology & Therapeutics 97, 587-596 (2015).
18. Ahmed, A.I.A., Van Der Marck, M.A., Van Den Elsen, G.A.H. & Olde Rikkert, M.G.M. Cannabinoids in Late-Onset Alzheimer's Disease. CPT Pharmacology & Therapeutics 97, 597-606 (2015).
19. Parker, L.A., Rock, E.M., Sticht, M.A., Wills, K.L. & Limebeer, C.L. Cannabinoids Suppress Acute and Anticipatory Nausea in Preclinical Rat Models of Conditioned Gaping. CPT Pharmacology & Therapeutics 97, 559-561 (2015).
20. Le Foll, B., Gorelick, D.A. & Goldberg, S.R. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl). 205, 171-174 (2009).
21. Hirvonen, J. In Vivo Imaging of the Cannabinoid CB1 Receptor With Positron Emission Tomography. CPT Pharmacology & Therapeutics 97, 565-567 (2015).
22. Ware, M.A. & Ziemianski, D. Medical Education on Cannabis and Cannabinoids: Perspectives, Challenges, and Opportunities. CPT Pharmacology & Therapeutics 97, 548-550 (2015).